{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:27:46Z","timestamp":1790342866625,"version":"4.1.0"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Invasive fungal infections (IFIs) are associated with high mortality rates and large economic burdens. Triazole prophylaxis is used for at-risk patients with hematological malignancies or stem cell transplants. We evaluated both the efficacy and the cost-effectiveness of triazole prophylaxis. A network meta-analysis (NMA) of randomized controlled trials (RCTs) evaluating fluconazole, itraconazole capsule and solution, posaconazole, and voriconazole was conducted. The outcomes of interest included the incidences of IFIs and deaths. This was coupled with a cost-effectiveness analysis from patient perspective over a lifetime horizon. Probabilities of transitions between health states were derived from the NMA. Resource use and costs were obtained from the Singapore health care institution. Data on 5,505 participants in 21 RCTs were included. Other than itraconazole capsule, all triazole antifungals were effective in reducing IFIs. Posaconazole was better than fluconazole (odds ratio [OR], 0.35 [95% confidence interval [CI], 0.16 to 0.73]) and itraconazole capsule (OR, 0.25 [95% CI, 0.06 to 0.97]), but not voriconazole (OR, 1.31 [95% CI, 0.43 to 4.01]), in preventing IFIs. Posaconazole significantly reduced all-cause deaths, compared to placebo, fluconazole, and itraconazole solution (OR, 0.49 to 0.54 [95% CI, 0.28 to 0.88]). The incremental cost-effectiveness ratio for itraconazole solution was lower than that for posaconazole (Singapore dollars [SGD] 12,546 versus SGD 26,817 per IFI avoided and SGD 5,844 versus SGD 12,423 per LY saved) for transplant patients. For leukemia patients, itraconazole solution was the dominant strategy. Voriconazole was dominated by posaconazole. All triazole antifungals except itraconazole capsule were effective in preventing IFIs. Posaconazole was more efficacious in reducing IFIs and all-cause deaths than were fluconazole and itraconazole. Both itraconazole solution and posaconazole were cost-effective in the Singapore health care setting.<\/jats:p>","DOI":"10.1128\/aac.01985-15","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T01:35:21Z","timestamp":1446514521000},"page":"376-386","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":46,"title":["Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis"],"prefix":"10.1128","volume":"60","author":[{"given":"Ying Jiao","family":"Zhao","sequence":"first","affiliation":[{"name":"Pharmacy and Therapeutics Office, Group Corporate Development, National Healthcare Group, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Leng","family":"Khoo","sequence":"additional","affiliation":[{"name":"Pharmacy and Therapeutics Office, Group Corporate Development, National Healthcare Group, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Tan","sequence":"additional","affiliation":[{"name":"Pharmacoeconomics and Drug Utilisation, Health Products Regulation Group, Health Sciences Authority, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Teng","sequence":"additional","affiliation":[{"name":"Pharmacy and Therapeutics Office, Group Corporate Development, National Healthcare Group, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Tee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National University Health System, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ban Hock","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine and Infectious Diseases, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ong","sequence":"additional","affiliation":[{"name":"Pharmacoeconomics and Drug Utilisation, Health Products Regulation Group, Health Sciences Authority, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Peng","family":"Lim","sequence":"additional","affiliation":[{"name":"Pharmacy and Therapeutics Office, Group Corporate Development, National Healthcare Group, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Yi Ann","family":"Chai","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Medicine Cluster, National University Health System, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/318483"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/591531"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_3_3_5_2","unstructured":"National Comprehensive Cancer Network. 2015. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology (NCCN guidelines) for prevention and treatment of cancer-related infections version 1. National Comprehensive Cancer Network Fort Washington PA."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/504810"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-7646(02)00019-5"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1356"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq076"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/11206800-000000000-00000"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120599"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt068"},{"key":"e_1_3_3_15_2","unstructured":"Higgins PTJ Green S (ed). 2011. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration London United Kingdom. www.cochrane-handbook.org."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00486.x"},{"key":"e_1_3_3_20_2","unstructured":"Singapore Department of Statistics. 2015. Population trends 2014. Department of Statistics Ministry of Trade and Industry Singapore. http:\/\/www.singstat.gov.sg\/docs\/default-source\/default-document-library\/publications\/publications_and_papers\/population_and_population_structure\/population2014.pdf."},{"key":"e_1_3_3_21_2","first-page":"512","article-title":"Efficacy of different prophylactic antifungal regimens in bone marrow transplantation","volume":"80","author":"Annaloro C","year":"1995","unstructured":"Annaloro C, Oriana A, Tagliaferri E, Bertolli V, Della Volpe A, Soligo D, Ibatici A, Pozzoli E, Lambertenghi Deliliers GL. 1995. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 80:512\u2013517.","journal-title":"Haematologica"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000239184","article-title":"Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients","volume":"40","author":"Chandrasekar PH","year":"1994","unstructured":"Chandrasekar PH, Gatny CM. 1994. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Chemotherapy 40:136\u2013143.","journal-title":"Chemotherapy"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki440"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203263261301"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.06079"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08838.x"},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr KA","year":"2004","unstructured":"Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L. 2004. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103:1527\u20131533.","journal-title":"Blood"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0783-3"},{"key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/515129","article-title":"Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial","volume":"28","author":"Menichetti F","year":"1999","unstructured":"Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagano L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F. 1999. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 28:250\u2013255.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/313654"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705418"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/515128"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.4.1035"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.5414\/CP201880"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1545"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2007.07.003"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268151"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-7-199304010-00003"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-9-200305060-00006"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.71.835.284"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt329"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01985-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01985-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:33:27Z","timestamp":1645475607000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01985-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1128\/AAC.01985-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01985-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2015-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}